The stock of Oncolytics Biotech Inc. (NASDAQ:ONCY) last traded at $1.62, up 0.62% from the previous session.
Data from the available sources indicates that Oncolytics Biotech Inc. (NASDAQ:ONCY) is covered by 5 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $3.00, we find $6.00. Given the previous closing price of $1.61, this indicates a potential upside of 272.67 percent. ONCY stock price is now -0.15% away from the 50-day moving average and 21.34% away from the 200-day moving average. The market capitalization of the company currently stands at $95.18M.
In total, 0 analysts have assigned it a hold rating, and 5 have given it a buy rating. Brokers who have rated the stock have averaged $6.93 as their price target over the next twelve months.
With the price target of $3, Maxim Group recently initiated with Buy rating for Oncolytics Biotech Inc. (NASDAQ: ONCY). On February 17, 2021, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $15.
A total of 1.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ONCY stock. A new stake in Oncolytics Biotech Inc. shares was purchased by NEWMAN DIGNAN & SHEERAR, INC. during the first quarter worth $21,000. In total, there are 43 active investors with 2.50% ownership of the company’s stock.
With an opening price of $1.6600 on Tuesday morning, Oncolytics Biotech Inc. (NASDAQ: ONCY) set off the trading day. During the past 12 months, Oncolytics Biotech Inc. has had a low of $0.80 and a high of $2.28. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 10.40, and a quick ratio of 10.40. The fifty day moving average price for ONCY is $1.6302 and a two-hundred day moving average price translates $1.3352 for the stock.
The latest earnings results from Oncolytics Biotech Inc. (NASDAQ: ONCY) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.07, beating analysts’ expectations of -$0.08 by 0.01. This compares to -$0.07 EPS in the same period last year. The company reported revenue of $4.64 million for the quarter, compared to $4.89 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.05 percent.
Oncolytics Biotech Inc.(ONCY) Company Profile
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.